GWILX
Price
$15.50
Change
+$0.19 (+1.24%)
Updated
Dec 20 closing price
RMFCX
Price
$54.97
Change
+$0.24 (+0.44%)
Updated
Dec 23 closing price
Ad is loading...

GWILX vs RMFCX

Header iconGWILX vs RMFCX Comparison
Open Charts GWILX vs RMFCXBanner chart's image
Glenmede Women in Leadership US Eq
Price$15.50
Change+$0.19 (+1.24%)
VolumeN/A
CapitalizationN/A
American Funds American Mutual R3
Price$54.97
Change+$0.24 (+0.44%)
VolumeN/A
CapitalizationN/A
GWILX vs RMFCX Comparison Chart
Loading...
View a ticker or compare two or three
VS
GWILX vs. RMFCX commentary
Dec 24, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GWILX is a Buy and RMFCX is a Buy.

FUNDAMENTALS
Fundamentals
RMFCX has more cash in the bank: 102B vs. GWILX (23.4M). RMFCX pays higher dividends than GWILX: RMFCX (1.69) vs GWILX (0.94). GWILX was incepted earlier than RMFCX: GWILX (9 years) vs RMFCX (23 years). GWILX is a more actively managed with annual turnover of: 83.00 vs. RMFCX (25.00). GWILX has a lower initial minimum investment than RMFCX: GWILX (0) vs RMFCX (250). RMFCX annual gain was more profitable for investors over the last year : 11.11 vs. GWILX (4.08). RMFCX return over 5 years is better than : 37.80 vs. GWILX (9.52).
GWILXRMFCXGWILX / RMFCX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence9 years23 years-
Gain YTD3.3899.92134%
Front LoadN/AN/A-
Min. Initial Investment0250-
Min. Initial Investment IRAN/AN/A-
Net Assets23.4M102B0%
Annual Yield % from dividends0.941.6955%
Returns for 1 year4.0811.1137%
Returns for 3 years1.2812.3810%
Returns for 5 years9.5237.8025%
Returns for 10 yearsN/A59.36-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
QURE16.981.51
+9.76%
uniQure NV
HAYW15.440.10
+0.65%
Hayward Holdings
TER125.950.76
+0.61%
Teradyne
ISPO3.36-0.06
-1.75%
Inspirato
ADCT1.96-0.16
-7.55%
ADC Therapeutics SA